Source: http://www.google.com/patents/US4714457?dq=6101531
Timestamp: 2015-05-04 03:14:43
Document Index: 428119218

Matched Legal Cases: ['arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19', 'arts 19']

Patent US4714457 - Method and apparatus for use in preparation of fibrinogen from a patient's blood - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsIn the preparation of concentrated fibrinogen extracted from the blood for making fibrin glue for use, e.g., as tissue adhesive or intra-arterial embolizing agent, the blood and subsequently obtained plasma are separated by centrifuging. In order to efficiently and rapidly prepare a small quantity of...http://www.google.com/patents/US4714457?utm_source=gb-gplus-sharePatent US4714457 - Method and apparatus for use in preparation of fibrinogen from a patient's bloodAdvanced Patent SearchPublication numberUS4714457 APublication typeGrantApplication numberUS 06/906,894Publication dateDec 22, 1987Filing dateSep 15, 1986Priority dateSep 15, 1986Fee statusLapsedPublication number06906894, 906894, US 4714457 A, US 4714457A, US-A-4714457, US4714457 A, US4714457AInventorsRobert AlterbaumOriginal AssigneeRobert AlterbaumExport CitationBiBTeX, EndNote, RefManPatent Citations (4), Referenced by (116), Classifications (12), Legal Events (4) External Links: USPTO, USPTO Assignment, EspacenetMethod and apparatus for use in preparation of fibrinogen from a patient's blood
US 4714457 AAbstract
In the preparation of concentrated fibrinogen extracted from the blood for making fibrin glue for use, e.g., as tissue adhesive or intra-arterial embolizing agent, the blood and subsequently obtained plasma are separated by centrifuging. In order to efficiently and rapidly prepare a small quantity of fibrinogen from a patient's own blood to be administered to the same patient during imminent surgery, an arrangement is disclosed wherein the blood or plasma to be centrifuged is transferred to a flat bag or packet which is then fitted into an insert fixture assembly which reliably secures the packet in the centrifuge cup in a suitable orientation.
1. A method for use in the autologous preparation of fibrin glue wherein a patient's blood is separated in a centrifuge having cylindral cups pivotally mounted to a rotor to obtain plasma and wherein the plasma is separated in the centrifuge to produce concentrated fibrinogen, comprising the steps of:(A) transferring the blood or plasma into a substantially flat packet; (B) fixing the packet containing the blood or plasma in a recess of a substantially cylindrical insert fixture assembly; (C) inserting said cylindrical-shaped insert fixture assembly in a cup of the centrifuge having a complementary cylindrical shape so that the insert fixture assembly is held snugly within said centrifuge cup; (D) centrifuging the blood or plasma contained within said packet fixed in said insert fixture assembly held in said centrifuge cup to separate the blood or plasma into components; and (E) forming fibrin glue from one of said separated components. 2. Method of claim 1 comprising the additional steps of:extracting blood from the patient; mixing the blood with anti-coagulant; carrying out steps (A)-(D) to form supernatant plasma; transferring the supernatant plasma to a second substantially flat packet; freezing said plasma in said second packet; thawing said plasma in said second packet; repeating steps (A)-(D) with said second packet containing the plasma to form liquid plasma and fibrinogen cryoprecipitate which adheres to the interior walls of the second packet; withdrawing the liquid plasma from the second packet; allowing said fibrinogen cryoprecipitate to melt into a liquid; withdrawing said liquid fibrinogen from the second packet; and mixing said fibrinogen with thrombin to form fibrin glue 3. The method of claim 2 wherein:the blood is centrifuged for a time in the range of about 3 to 10 minutes; the supernatant plasma is frozen for a time in the range of about 1/2 to 11/2 hours; the frozen plasma is stored for a time in the range of between of about 15 to 20 minutes; and the thawed plasma is centrifuged for a time in the range of between about 5 to 20 minutes. 4. The method of claim 3, wherein:the blood is centrifuged at a temperature in the range of between about 0� C. to 5� C.; the plasma is frozen at a temperature in the range of between about -40� C. to -100� C.; the frozen plasma is thawed at a temperature in the range of beteen about 0� C. to 5� C.; and the thawed plasma is centrifuged at a temperature in the range of between about 0� C. to 5� C. 5. The method of claim 1, wherein:about 40 to 50 ml of blood is extracted from the patient; and about 1 to 1.5 ml of the fibrinogen cryoprecipitate is produced. 6. The method of claim 1, wherein the step of inserting the cylindrical shaped insert fixture assembly into the cup of the centrifuge is carried out so that a plane containing the flat packet also contains the pivot axis of the centrifuge cup.
7. The method of claim 1 wherein said substantially flat packet has relatively small capacity.
8. The method of claim 7 wherein said substantially flat packet has a capacity of about 150 ml.
The present invention relates generally to the preparation of concentrated fibrinogen from blood for making fibrin glue and, more particularly, to the autologous preparation of relatively small quantities of concentrated fibrinogen for making fibrin glue.
Fibrin glue has been found to have widespread applications in various medical and surgical procedures. For example, fibrin glue is used as an adhesive for sealing various internal wounds or incisions in body organs. The glue also serves as a good tissue adhesive. Concentrated fibrinogen, which is used in making the fibrin glue, is initially prepared from human blood and stored for use at a later time during surgery.
A description of a technique for preparing fibrin glue from blood may be found, e.g., in Vascular Surgery, Volume 17, No. 5, September/October 1983, pp. 294-304. Generally, the amount of blood is collected and, after addition of sodium citrate as an anti-coagulant, centrifuged to form supernatant plasma. The plasma is collected and then frozen, e.g., at -80� C. for at least 6 hours. The frozen plasma can be stored for periods of over one year. Just prior to surgery, the frozen plasma is thawed at 4� C. for six hours. The thawed plasma is cold centrifuged to obtain a sediment of concentrated fibrinogen. Thrombin is added to the fibrinogen during the surgical procedure to produce fibrin glue for administration to the patient.
While this technique for preparing concentrated fibrinogen from the blood of one individual and administering fibrin glue produced from the fibrinogen to another individual has been widely adopted in Europe, its use is not presently permitted in the United States due to the possibility of transmission of infectious diseases, such as hepatitis or AIDS, from one individual to another. Accordingly, in the United States, only autologous synthesis and use of fibrin glue, i.e., preparation of the fibrin glue from the patient's own blood for use during his own imminent surgery is permitted. However, such autologous synthesis of fibrin glue has suffered from several drawbacks.
For example, it has not been possible to prepare relatively small quantities of concentrated fibrinogen for immediate use in a practical manner. The equipment and instruments for extracting the fibrinogen are generally large and located at places remote from the operating room. Such equipment is not suited for extraction and production of small quantities of fibrinogen.
Furthermore, since the preparation of larger quantities of concentrated fibrinogen requires longer times, the patient may be required to be admitted to the hospital earlier than otherwise indicated in order to provide sufficient time for the preparation of fibrinogen.
For these reasons, autologous preparation and use of fibrin glue has not been actively pursued in medical and surgical treatment in the United States.
Accordingly, it is an object of the present invention to provide new and improved methods and apparatus for use in the preparation of concentrated fibrinogen and fibrin glue.
Another object of the present invention is to provide new and improved methods and apparatus for use in autologous preparation of concentrated fibrinogen and fibrin glue produced therefrom.
A further object of the present invention is to provide new and improved methods and apparatus for use in autologous preparation of concentrated fibrinogen by which such production is completed in a more rapid manner than has been possible heretofore.
A still further object of the present invention is to provide new and improved methods and apparatus for use in autologous preparation of concentrated fibrinogen in more appropriate smaller quantities than has been practical heretofore.
Yet another object of the present invention is to provide new and improved methods and apparatus for use in autologous preparation of concentrated fibrinogen by which fibrin glue produced therefrom has improved tensile strength.
Briefly, these and other objects are obtained by providing an arrangement by which the centrifuging steps used in the preparation of the concentrated fibrinogen from which the fibrin glue is prepared are rendered specifically applicable to autologous preparation from a patient's own blood for administration to the same patient during imminent surgery. The arrangement comprises a small flat bag or packet into which the blood or plasma to be centrifuged is transferred, and an insert fixture assembly for receiving the packet and reliably securing the same in the centrifuge cup in a suitable orientation.
In an illustrated embodiment, the insert fixture assembly includes a cylindrical fixture comprising a pair of substantially semi-cylindrical parts having concave mating surfaces which define a recess between them in which the blood or plasma-containing packet is held by means of interengaging side edges of the mating surfaces and a support member attached to one of the fixture parts. The outer cylindrical configuration of the fixture permits the fixture which holds the blood or plasma-containing bag to be snugly fit within the centrifuge cup with the packet oriented in a suitable direction.
The arrangement of the invention permits smaller quantities of concentrated fibrinogen to be extracted from the blood in a shorter time than has been possible heretofore. The flat bag or packet provides maximum surface area on which the sediment of concentrated fibrinogen can be deposited.
A more complete appreciation of the present invention and many of the attendent advantages thereof will be readily understood by reference to the following detailed description when considered in connection with the accompanying drawings in which:
FIG. 1 is a schematic illustration showing the various steps in autologous preparation of concentrated fibrinogen utilizing a method and apparatus in accordance with the invention;
FIG. 2 is a perspective view, partially broken away, of a conventional centrifuge rotor for use in a method in accordance with the invention;
FIG. 3 is a side elevation view of the packet comprising one component of apparatus in accordance with the invention;
FIG. 4 is a perspective view of a support member comprising one component of an insert fixture assembly in accordance with the present invention; and
FIG. 5 is an exploded perspective view, partially broken away, illustrating a packet held in an insert fixture assembly in accordance with the invention and further illustrating insertion of the assembly into a centrifuge cup.
Referring now to the drawings wherein like reference characters designate identical or corresponding parts throughout the several views, and more particularly to FIG. 1, a method of autologous preparation of concentrated fibrinogen and fibrin glue in accordance with the invention will now be described. As illustrated in FIG. 1, blood 3 is extracted from the patient in a conventional manner by a syringe 13, and is transferred through a tube 2 into a flat bag or packet 1, preferably formed of plastic. The blood is mixed with an anti-coagulant in packet 1. The packet 1 is of a relatively small size, e.g., 150 ml capacity. For example, a Transfer Pack available from Fenwal Laboratories, a division of Travenol Laboratories, Inc. of Deerfield, Illinois may be utilized. The packet 1 is substantially rectangular and has a pair of apertures 4 and 5 formed through its top.
The packet 1 is positioned in a substantially cylindrical insert fixture assembly 6 and the fixture assembly 6 holding packet 1 is placed in one of the cups 8 of a conventional centrifuge 7. For example, the centrifuge may be a Sorvall Model H-4000 provided with a model HG-4L swinging bucket rotor.
The blood 3 is centrifuged, for example, at 2000 rpm for about 5 minutes to separate the same into plasma supernatant 9 and sediment 10 of red blood cells. The plasma supernatant 9 is transferred through a plasma extractor 15 into a second packet 1', similar to the first packet 1, provided with apertures 4' and 5'. At this point, the plasma 9 in the second packet 1' is frozen, e.g., for about one hour at -80� C. The frozen plasma 9 is then thawed by placing the packet 1' into a circulating water bath 11. Thawing takes place after 15 to 30 minutes at a bath temperature of -4� C. to -2� C., and can be accelerated by manually breaking-up the frozen contents of the packet 1' to increase the surface area thereof.
The second packet 1' is then removed from the waterbath 11 and quickly placed within the fixture assembly 6 whereupon the fixture assembly holding packet 1' is inserted into a cup 8 of centrifuge 7. Centrifuging of the plasma is then carried out in a controlled temperature environment, e.g., at a temperature of about 0� C. to +4� C., at about 4000 rpm for about 10 minutes.
The second centrifuging step results in the separation of the plasma into supernatant plasma 9' and cryoprecipitate 12 of concentrated fibrinogen, the latter being deposited on the interior surfaces of packet 1'. The supernatant plasma 9' is transferred into a third packet 1" similar to packets 1 and 1'. The cryoprecipitate 12 adhering to the interior surfaces of the second packet 1' remains.
The frozen cryoprecipitate 12 of concentrated fibrinogen is allowed to melt into a liquid 12' by allowing the packet 1' to reach room temperature. Thus, the cryoprecipitate turns to liquid within a few minutes and can be extracted with a tuberculin syringe 28. Extraction of the liquid cryoprecipitate is facilitated by injecting about 10 cc of air into the second packet 1'.
The concentrated fibrinogen 12' in liquid form is administered to the situs of application, e.g., a wound or incision in the patient, with a substantially equal amount of thrombin then also being applied to form the fibrin glue. After about one minute, the fibrinogen is converted in situ to fibrin glue.
The blood in the first packet 1 may be centrifuged for about 3 to 10 minutes at a temperature of about 0� C. to +5� C. with the supernatant plasma then being frozen at a temperature of about -40� C. to -100� C. for about 1/2-11/2 hours, the frozen plasma then being thawed at a temperature of about 0� C. to +5� C. for about 15 to 30 minutes. The thawed plasma is then centrifuged in the second packet 1' at about 0� C. for about 5 to 20 minutes. Thus, only about 40 to 50 ml of blood need be extracted from a patient to produce about 1 to 1.5 ml of the fibrinogen cyroprecipitate that is required to form the glue.
Referring to FIG. 2, the centrifuge 7 comprises a rotor 14 to which four cylindrical cups 8 are pivotally connected. Such a centrifuge 7 is usually found in most hospitals and medical centers. Each of the cups 8 is designed to hold a large quantity of liquid, e.g., about 1000 to 1500 ml, to be centrifuged. This is a considerable amount and much greater than any amount of blood or plasma that is to be centrifuged for synthesizing fibrinogen for the fibrin glue. In particular, only about 45 millileters of blood is required to be centrifuged in the autologous preparation of fibrin concentrate. It is therefore seen that the conventional centrifuge is generally not suitable for centrifuging the small amount of blood and plasma required in the autologous preparation of fibrin glue.
Referring to FIG. 3, packet 1 is generally flat and comprises apertures 4 and 5 at its upper end as described above. A feed tube 2 communicates with the interior of the packet 1 and a second conduit 16 which is normally sealed at 17 between two lips or extensions 18 (only one shown) also communicates with the interior of packet 1. The important characteristic of the packet is that it be generally flat and have a relatively small capacity, e.g. about 150 ml.
Referring to FIGS. 4 AND 5, the insert fixture assembly 6 which is inserted into one of the centrifuge cups 8 in the direction of arrow K (FIG. 5) comprises a pair of substantially semi-cylindrical parts 19 and 20 and a support member 24. The parts 19 and 20 have concave mating surfaces which abut along their axial side edges 19' and 20' to define a recess 21 between the mating surfaces. It will be understood that the particular shape of the recess 21 formed between the mating surfaces of parts 19 and 20 is not limited to this particular shape although it is desirable that the packets 1 and 1' seat against the surfaces of the recess 21 to the maximum extent possible. Therefore, as seen in FIG. 2, the long edges of packets 1 and 1' will be sandwiched between the side edges 19' and 20' of parts 19 and 20 so that the packets 1 and 1' are securely held in the cylindrical fixture within recess 21.
Referring to FIG. 4, the support member 24 is substantially U-shaped and comprises bent edges 25, 26 which are adapted to fit into respective holes 22 and 23, formed in one of the parts 19 or 20 as seen in FIG. 5. The legs of the support member 24 are adapted to pass through respective apertures 4, 5; 4', 5' of packet 1; 1' so that the packet 1; 1' is preferably seated against the internal mating surfaces of parts 19 and 20 as seen in FIG. 5 when the respective ends 25 and 26 of the support member 24 are inserted into the holes 22 and 23 of the insert fixture assembly 6. In this manner, the packet 1; 1' will be retained within the recess 21 formed between he internal mating surfaces of parts 19 and 20 and will be seated against at least one of the internal surfaces of these parts.
The use of the support member in fixing the packet within the recess of the cylindrical fixture prevents any torsion from being applied to the packet. The recess 21 between parts 19 and 20 is formed so that a packet 1 or 1' containing the blood or plasma contacts as much of the internal concave surfaces of the parts 19 and 20 as possible. This provides a secure seating of the packet 1 or 1' within the cylindrical fixture 6 allowing for effective separation of the blood or plasma component as noted above.
As illustrated in FIGS. 2 and 5, the centrifuge cups 8 are pivotally mounted to the rotor to swing outwardly about an axle 27 which defines the pivot axis of each cup. As seen in FIG. 5, the cylindrical insert fixture assembly 6 is inserted into the cup 8 so that a plane passing through the flat bag or packet substantially contains the pivot axis of the cup. This orientation promotes uniformity and efficiency of the centrifuging operation despite the relatively small quantities of blood and plasma being centrifuged.
The cylindrical insert fixture assembly 6 is shaped so as to fit snugly within the centrifuge cup 8, as illustrated in FIG. 5. In particular, the insert fixture assembly 6 formed by parts 19 and 20 is shaped to have dimensions complementary with the interior dimensions of the cup 8. When the parts 19 and 20 are thus inserted within a cup 8, the parts are held fast against each other to clamp or sandwich the edges of the packet between the side edges 19' and 20' of parts 19 and 20. In the illustrated embodiment, the insert fixture assembly preferably has a length of about 5 to 8 inches, a diameter of about 3 to 5 inches and recess 21 has a volume of about 5 to 15 cubic inches to accommodate the packet 1 or 1'. The insert fixture assembly 6 has a length of about 6 inches and a diameter of about 35/8 inches with the recess 21 having concavely curved surfaces. The support member 24 is about 21/2 inches long and the bent ends 25 and 26 each have a length of about 1 inch. The parts 19 and 20 are preferably constructed of styrofoam material.
As noted above, the invention enables smaller quantities of fibrinogen to be prepared more quickly than has been possible heretofore, thereby making autologous preparation of fibrin glue practical. The invention will be explained further by way of the following example:
A portable kit for preparation of fibrin glue from fibrinogen in accordance with the present invention, is prepared to contain 3.8% sodium citrate, bacteriostatic water, a 60-ml sterile syringe 13, three Fenwal Transfer Pack Units 1, 1', 1", one Sample Site (plasma) Extractor 15 (Fenwal), an 8- by 8- by 2- inch polyethylene tray 11, two styrofoam parts 19 and 20, one wire clamp support member 24, a submersible battery-operated pump conventionally available from Edmund Scientific, two alligator clip leads and a battery holder containing two D-cell batteries conventionally available from Radio Shack, unreconstituted bovine thrombin, and two sterile tuberculin syringes 28 with plastic cannulas.
Preparation of the fibrinogen and fibrin glue is done directly at the blood bank, i.e. in the hospital or medical center during or just before surgery. The temperature of centrifuge 7 was set at 4� C., with the polyethylene tray 11 being partially filled with 0.9% saline solution and placed inside the centrifuge 7 to prepare the 4� C. waterbath. The 46.7% sodium citrate was diluted to 3.8% by addition of the bacteriostatic water, at one part of citrate to 11 parts water. 5 ml of the dilute citrate was drawn into the 60 ml syringe 13, 45 ml of blood was collected into the citrate containing syringe 13 (FIG. 1). Gentle motion of the blood-containing syringe 13 ensures proper anticoagulation.
The blood was then transferred into a Transfer Pack unit or packet 1 through the side port tubing 2. About 10 cc of air was retained in the packet 1 to provide necessary volume during the subsequent centrifuging. The side tubing 2 was then sealed, and cut at a distance of one inch from the packet 1.
The substantially U-shaped support member 24 was then inserted through the holes 4 and 5 located at the upper edge of the packet 1. The packet 1 was then disposed between parts 19 and 20 as illustrated in FIG. 5, with the prongs 25 and 26 of the support member 24 being inserted into respective holes 22 and 23 in the sleeve member 20. The insert fixture assembly was then introduced into one of the centrifuge cups or buckets 8 as seen in FIG, 5. A cup 8 opposite the cup into which the sleeve 6 was inserted, was then balanced, with centrifuging then proceeding at 2000 rpm for five minutes at 4� C. The resulting supernatant plasma 9 (FIG. 1) was transferred into a second packet or bag 1' using the plasma extractor 15. This supernatant plasma 9 was then frozen at -80� C. for one hour.
The circulating waterbath was prepared by placing the submersible pump into the saline tray 11 (FIG. 1) located inside the centrifuge, with proper connection of leads to the batteries. The frozen plasma was then placed in the circulating waterbath 11, and allowed to thaw for between 15 and 30 minutes. The thawing could be accelerated by manually breaking-up the frozen contents to increase surface area.
The second packet was then removed from the bath 11, quickly disposed into the insert fixture assembly 6 in the same manner as the first packet 1, and secured with the clamp 24. The assembly was again inserted into a cup 8 of the centrifuge, with the opposite cup being balanced, and centrifuging then proceeding at 4000 rpm for ten minutes. This second centrifuging step formed supernatant plasma 9' and cryoprecipitate deposit 12 along the internal walls of the packet 1'. All the supernatant plasma 9' was removed into a third packet 1" with the plasma extractor 15, leaving the cryoprecipitate 12 adhering to the internal wall of the second packet 1'.
Within a few minutes, e.g. about five to 10 minutes, the cryoprecipate deposit 12 turns into liquid, and is extracted with a tuberculin syringe 28 and is ready for use. Injection of about 10 cc of air into the second transfer packet 1' facilitates the extraction in the direction of arrow J. About 1-1.5 ml of cryoprecipitate is formed from the 45 ml of blood initially extracted.
Next, a few drops of the reconstituted thrombin was added to the fibrinogen concentrate that was removed, to convert the fibrinogen into fibrin glue. The resulting fibrin glue is easily applied to the situs of an injury, wound, or incision, of the patient with a tuberculin syringe 28 fitted with a Teflon cannula.
The entire preparation of the fibrin glue from the initial withdrawal of blood from the patient, is accomplished well within three hours. This is in contrast to the previously utilized procedures, which required at least twelve hours to prepare the required glue product. At the same time, much smaller quantities of the fibrin glue can be prepared.
Furthermore, repeated studies have confirmed that the fibrin glue prepared in accordance with this technique, exhibits a tensile strength of at least 3 g/mm2.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4253458 *Mar 8, 1979Mar 3, 1981Baxter Travenol Laboratories, Inc.Method and apparatus for collecting blood plasmaUS4303193 *Jan 22, 1979Dec 1, 1981Haemonetics CorporationApparatus for separating blood into components thereofUS4413773 *Sep 29, 1980Nov 8, 1983E. I. Du Pont De Nemours And CompanyMethod and apparatus for centrifugal separationUS4617009 *Nov 28, 1983Oct 14, 1986Seroteknik HgMethod and apparatus for centrifugal batch separation of blood* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS5030215 *Jan 3, 1990Jul 9, 1991Cryolife, Inc.Preparation of fibrinogen/factor XIII precipitateUS5100564 *Nov 6, 1990Mar 31, 1992Pall CorporationBlood collection and processing systemUS5217627 *Nov 6, 1991Jun 8, 1993Pall CorporationSystem and method for processing biological fluidUS5302299 *Mar 20, 1992Apr 12, 1994Pall CorporationBiological semi-fluid processing assemblyUS5318782 *Feb 25, 1993Jun 7, 1994Weis Fogh Ulla SMethod for preparing tissue repair promoting substancesUS5360545 *Aug 3, 1993Nov 1, 1994Pall CorporationFilter for obtaining plateletsUS5462716 *Nov 10, 1992Oct 31, 1995Holm; Niels E.Container for receiving and separating a fluid, preferably blood plasma, into its ingredientsUS5480378 *Aug 24, 1994Jan 2, 1996Weis-Fogh; UllaApparatus for preparing a concentrate of coagulation factors from a blood sampleUS5520885 *Jan 19, 1993May 28, 1996Thermogenesis CorporationFibrinogen processing apparatus, method and containerUS5578326 *May 12, 1995Nov 26, 1996E. R. Squibb & Sons, Inc.Method and an apparatus for preparing tissue repair promoting substancesUS5585007 *Dec 7, 1994Dec 17, 1996Plasmaseal CorporationPlasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealantUS5587070 *Jun 4, 1993Dec 24, 1996Pall CorporationSystem for processing biological fluidUS5616254 *May 26, 1995Apr 1, 1997Pall CorporationSystem and method for processing biological fluidUS5658533 *Jun 6, 1995Aug 19, 1997E.R. Squibb & Sons, Inc.Container for receiving and separating a fluid into its ingredientsUS5672481 *Apr 23, 1993Sep 30, 1997Cellpro, IncorporatedApparatus and method for particle separation in a closed fieldUS5674458 *Jun 6, 1995Oct 7, 1997E. R. Squibb & Sons, Inc.Container for receiving and separating a fluid into its ingredientsUS5707331 *May 5, 1995Jan 13, 1998John R. WellsAutomatic multiple-decanting centrifugeUS5739288 *May 26, 1995Apr 14, 1998Bristol-Myers Squibb CompanyFibrin sealant compositionsUS5746979 *Jun 6, 1995May 5, 1998F. R, Squibb & Sons, Inc.Method for receiving and separating a fluid into its ingredientsUS5750657 *Oct 18, 1993May 12, 1998Bristol-Myers Squibb CompanyMethods and compositions using fibrin monomer to make a fibrin sealantUS5763410 *Jun 2, 1995Jun 9, 1998Bristol-Myers Squibb CompanyKit for preparing a fibrin sealantUS5763411 *Jun 2, 1995Jun 9, 1998Bristol-Myers Squibb CompanyNondynamic fibrin monomer on bandages, sutures, prostheses and dressingsUS5770194 *May 25, 1995Jun 23, 1998Bristol-Myers Squibb CompanyFibrin sealant compositions and methods for utilizing sameUS5773418 *Nov 20, 1997Jun 30, 1998Bristol-Myers Squibb CompanyFibrin sealant compositions and methods for utilizing sameUS5788662 *Oct 22, 1996Aug 4, 1998Plasmaseal LlcMethods for making concentrated plasma and/or tissue sealantUS5795571 *Nov 15, 1996Aug 18, 1998Bristol-Myers Squibb CompanyComposition containing autologous thrombin blood fraction for use in a medical procedureUS5795780 *Nov 15, 1996Aug 18, 1998Bristol-Myers Squibb CompanyMethod of use of autologous thrombin blood fraction in a cell culture with keratinocytesUS5804428 *Mar 31, 1998Sep 8, 1998Bristol-Myers Squibb CompanyFibrin sealant compositions and methods for utilizing sameUS5895346 *Oct 6, 1997Apr 20, 1999Wells; John R.Automatic multiple-decanting centrifugeUS5962026 *May 31, 1995Oct 5, 1999Bristol-Myers Squibb CompanySolid compositions of fibrin monomerUS6054122 *Jun 7, 1995Apr 25, 2000The American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and useUS6077507 *Mar 26, 1997Jun 20, 2000Bristol-Myers Squibb CompanyMethod of making a composition comprising a fibrin monomerUS6083383 *Jun 25, 1998Jul 4, 2000Huang; Xun YangApparatus for production of fibrin ogen or fibrin glueUS6110484 *Nov 24, 1998Aug 29, 2000Cohesion Technologies, Inc.Collagen-polymer matrices with differential biodegradabilityUS6117425 *Jun 7, 1995Sep 12, 2000The American National Red CrossSupplemented and unsupplemented tissue sealants, method of their production and useUS6197325Jun 7, 1995Mar 6, 2001The American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and useUS6214338Apr 25, 2000Apr 10, 2001Plasmaseal LlcPlasma concentrate and method of processing blood for sameUS6274090Aug 5, 1998Aug 14, 2001Thermogenesis Corp.Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed therebyUS6277394Jun 16, 2000Aug 21, 2001Cohesion Technologies, Inc.Collagen-polymer matrices with differential biodegradabilityUS6284285Dec 29, 1992Sep 4, 2001E. R. Squibb & Sons, Inc.Tissue repair promoting compositionUS6398972Apr 11, 2000Jun 4, 2002Harvest Technologies CorporationMethod for producing platelet rich plasma and/or platelet concentrateUS6472162Jun 4, 1999Oct 29, 2002Thermogenesis Corp.Method for preparing thrombin for use in a biological glueUS6559119Jun 7, 1995May 6, 2003Loyola University Of ChicagoMethod of preparing a tissue sealant-treated biomedical materialUS6582349Sep 26, 2000Jun 24, 2003Baxter International Inc.Blood processing systemUS6623959Jun 13, 2001Sep 23, 2003Ethicon, Inc.Devices and methods for cell harvestingUS6648911Nov 20, 2000Nov 18, 2003Avantec Vascular CorporationMethod and device for the treatment of vulnerable tissue siteUS6762336May 19, 1999Jul 13, 2004The American National Red CrossHemostatic sandwich bandageUS7001321 *Mar 30, 1998Feb 21, 2006Baxter International Inc.Carrier for holding a flexible fluid processing containerUS7056722Nov 10, 2000Jun 6, 2006Thermogenesis Corp.Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed therebyUS7175336Jan 26, 2001Feb 13, 2007Depuy Acromed, Inc.Graft delivery systemUS7189410Jun 7, 1995Mar 13, 2007The American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and useUS7196054Jun 7, 1995Mar 27, 2007The American National Red CrossMethods for treating wound tissue and forming a supplemented fibrin matrixUS7208179Jun 7, 1995Apr 24, 2007The American National Red CrossMethods for treating disease and forming a supplemented fibrin matrixUS7229959Jun 7, 1995Jun 12, 2007The American National Red CrossSupplemented fibrin matrix delivery systemsUS7374678Sep 2, 2004May 20, 2008Biomet Biologics, Inc.Apparatus and method for separating and concentrating fluids containing multiple componentsUS7413652Apr 26, 2005Aug 19, 2008Arteriocyte Medical Systems, Inc.Method for the production of a blood component compositionUS7470371Oct 19, 2006Dec 30, 2008Hanuman LlcMethods and apparatus for isolating platelets from bloodUS7553413Jan 30, 2006Jun 30, 2009Hanuman LlcPlasma concentrator deviceUS7694828Apr 27, 2005Apr 13, 2010Biomet Manufacturing Corp.Method and apparatus for producing autologous clotting componentsUS7708152Jan 30, 2006May 4, 2010Hanuman LlcMethod and apparatus for preparing platelet rich plasma and concentrates thereofUS7766900Sep 8, 2005Aug 3, 2010Biomet Manufacturing Corp.Method and apparatus for application of a fluidUS7780860May 19, 2008Aug 24, 2010Biomet Biologics, LlcApparatus and method for separating and concentrating fluids containing multiple componentsUS7806276Apr 11, 2008Oct 5, 2010Hanuman, LlcBuoy suspension fractionation systemUS7824559Jan 30, 2006Nov 2, 2010Hanumann, LLCApparatus and method for preparing platelet rich plasma and concentrates thereofUS7832566May 25, 2006Nov 16, 2010Biomet Biologics, LlcMethod and apparatus for separating and concentrating a component from a multi-component material including macroparticlesUS7837708 *Apr 22, 2005Nov 23, 2010Arthrex, Inc.Accelerated healing with intraoperative combination of suture and autogenous blood componentsUS7837884Dec 29, 2008Nov 23, 2010Hanuman, LlcMethods and apparatus for isolating platelets from bloodUS7845499May 25, 2006Dec 7, 2010Biomet Biologics, LlcApparatus and method for separating and concentrating fluids containing multiple componentsUS7866485Jul 31, 2007Jan 11, 2011Hanuman, LlcApparatus and method for preparing platelet rich plasma and concentrates thereofUS7901584Jun 2, 2009Mar 8, 2011Hanuman, LlcPlasma concentrationUS7914689May 19, 2008Mar 29, 2011Biomet Biologics, LlcApparatus and method for separating and concentrating fluids containing multiple componentsUS7987995May 3, 2010Aug 2, 2011Hanuman, LlcMethod and apparatus for preparing platelet rich plasma and concentrates thereofUS7992725Apr 11, 2008Aug 9, 2011Biomet Biologics, LlcBuoy suspension fractionation systemUS8012077May 23, 2008Sep 6, 2011Biomet Biologics, LlcBlood separating deviceUS8048321Aug 11, 2010Nov 1, 2011Biomet Biologics, LlcApparatus and method for separating and concentrating fluids containing multiple componentsUS8062534Dec 6, 2010Nov 22, 2011Biomet Biologics, LlcApparatus and method for separating and concentrating fluids containing multiple componentsUS8096422Nov 1, 2010Jan 17, 2012Hanuman LlcApparatus and method for preparing platelet rich plasma and concentrates thereofUS8105495Jan 10, 2011Jan 31, 2012Hanuman, LlcMethod for preparing platelet rich plasma and concentrates thereofUS8119013Oct 4, 2010Feb 21, 2012Hanuman, LlcMethod of separating a selected component from a multiple component materialUS8133389Jul 29, 2011Mar 13, 2012Hanuman, LlcMethod and apparatus for preparing platelet rich plasma and concentrates thereofUS8163184Mar 25, 2011Apr 24, 2012Biomet Biologics, LlcApparatus and method for separating and concentrating fluids containing multiple componentsUS8182769Apr 4, 2008May 22, 2012Biomet Biologics, LlcClean transportation systemUS8187475Mar 6, 2009May 29, 2012Biomet Biologics, LlcMethod and apparatus for producing autologous thrombinUS8187477Nov 22, 2010May 29, 2012Hanuman, LlcMethods and apparatus for isolating platelets from bloodUS8206448 *Aug 17, 2005Jun 26, 2012Spinal Restoration, Inc.Injection of fibrin sealant using reconstituted components in spinal applicationsUS8394072Oct 5, 2009Mar 12, 2013Spinal Restoration, Inc.Injection of fibrin sealant including an anesthetic in spinal applicationsUS8403895Oct 5, 2009Mar 26, 2013Spinal Restoration, Inc.Injection of fibrin sealant including an anesthetic in spinal applicationsUS8444620Jul 8, 2010May 21, 2013Biomet Biologics, LlcMethod and apparatus for application of a fluidUS8445009Aug 6, 2007May 21, 2013Stb, LtdProcesses for the production of solid dressings for treating wounded tissueUS8480757Aug 28, 2006Jul 9, 2013Zimmer, Inc.Implants and methods for repair, replacement and treatment of diseaseUS8497121Mar 23, 2012Jul 30, 2013Zimmer Orthobiologics, Inc.Method of obtaining viable small tissue particles and use for tissue repairUS8518272Apr 4, 2008Aug 27, 2013Biomet Biologics, LlcSterile blood separating systemUS8518433Dec 15, 2011Aug 27, 2013Zimmer, Inc.Method of treating an osteochondral defectUS8524268Dec 15, 2011Sep 3, 2013Zimmer, Inc.Cadaveric allogenic human juvenile cartilage implantUS8551344Apr 9, 2010Oct 8, 2013Biomet Manufacturing, LlcMethod and apparatus for producing autologous clotting componentsUS8603346Sep 22, 2011Dec 10, 2013Biomet Biologics, LlcApparatus and method for separating and concentrating fluids containing multiple componentsUS8652507Dec 22, 2010Feb 18, 2014Zimmer, Inc.Juvenile cartilage compositionUS8679528Sep 28, 2012Mar 25, 2014American National Red CrossHemostatic dressingUS8765165Aug 23, 2010Jul 1, 2014Zimmer, Inc.Particulate cartilage systemUS8784863Dec 22, 2010Jul 22, 2014Zimmer, Inc.Particulate cadaveric allogenic cartilage systemUS8834914Dec 22, 2010Sep 16, 2014Zimmer, Inc.Treatment methods using a particulate cadaveric allogenic juvenile cartilage particlesUS8986304 *Jun 26, 2012Mar 24, 2015Bsnc Holding, LlcInjection of fibrin sealant using reconstituted components in spinal applicationsUS20060095075 *Aug 17, 2005May 4, 2006Burkinshaw Brian DInjection of fibrin sealant using reconstituted components in spinal applicationsUS20120328600 *Jun 26, 2012Dec 27, 2012Spinal Restorations, Inc.Injection of fibrin sealant using reconstituted components in spinal applicationsUSRE38730 *Apr 20, 2001Apr 26, 2005Harvest Technologies CorporationAutomatic multiple-decanting centrifuge and method of treating physiological fluidsUSRE38757 *Jan 13, 2000Jul 12, 2005Harvest Technologies CorporationAutomatic multiple-decanting centrifuge and container thereforUSRE39192 *Jun 20, 2003Jul 18, 2006American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and useUSRE39298 *Jun 20, 2003Sep 19, 2006The American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and useUSRE39321 *Jun 20, 2003Oct 3, 2006The American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and useCN1082840C *May 6, 1996Apr 17, 2002约翰�R�韦尔斯Automatic multiple-decanting centrifugeEP0740964A1 *Apr 30, 1996Nov 6, 1996Wells, John RaymondAutomatic multiple-decanting centrifugeEP1007183A1 *Jun 22, 1998Jun 14, 2000Baxter International Inc.Blood processing chamber counter-balanced with blood-free liquidWO1993009753A1 *Nov 10, 1992May 27, 1993Unes AsA container for receiving and separating a fluid, preferably blood plasma, into its ingredientsWO1997028834A1Feb 3, 1997Aug 14, 1997Richard D AntanavichMethod and apparatus for applying tissue sealantWO1998011925A1 *Sep 13, 1997Mar 26, 1998Benincasa CarloProcess of preparation of an autologous fibrin glueWO1999049977A1 *Mar 16, 1999Oct 7, 1999Baxter IntA carrier for holding a flexible fluid processing container* Cited by examinerClassifications U.S. Classification494/37, 494/45, 494/20, 494/21International ClassificationA61M1/36, B04B5/04Cooperative ClassificationB04B5/0421, B04B5/0428, A61M1/3693European ClassificationB04B5/04B4, A61M1/36Z, B04B5/04B2BLegal EventsDateCodeEventDescriptionFeb 27, 1996FPExpired due to failure to pay maintenance feeEffective date: 19951227Dec 24, 1995LAPSLapse for failure to pay maintenance feesAug 1, 1995REMIMaintenance fee reminder mailedJun 24, 1991FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services